Ming Y. Lim, MBBCh, MS

Languages Spoken: English

Dr. Ming Y. Lim is an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah since October 2018. She earned her medical degree at Cambridge University, England and completed her 2-year Foundation Training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting patients with congenital bleeding disorders, specifically hemophilia patients with inhibitors. She is the recipient of 2 foundation-sponsored grants to determine the epidemiology and risk factors for inhibitor development in non-severe hemophilia A patients. She has co-authored over 40 peer-reviewed publications.

Dr. Lim is the Medical Director for the Utah Center for Bleeding & Clotting Disorders at University of Utah Health. Nationally, she serves on the American Board of Internal Medicine Hematology Approval Committee and is the Chair of the American Society of Hematology Subcommittee on Stewardship and Systems-Based Hematology. She also serves on the National Comprehensive Cancer Network (NCCN) Cancer-Associated Venous Thromboembolic Disease Panel.

Dr. Ming Y. Lim is an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah since October 2018. She earned her medical degree at Cambridge University, England and completed her 2-year Foundation Training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting patients with congenital bleeding disorders, specifically hemophilia patients with inhibitors. She is the recipient of 2 foundation-sponsored grants to determine the epidemiology and risk factors for inhibitor development in non-severe hemophilia A patients. She has co-authored over 40 peer-reviewed publications.

Dr. Lim is the Medical Director for the Utah Center for Bleeding & Clotting Disorders at University of Utah Health. Nationally, she serves on the American Board of Internal Medicine Hematology Approval Committee and is the Chair of the American Society of Hematology Subcommittee on Stewardship and Systems-Based Hematology. She also serves on the National Comprehensive Cancer Network (NCCN) Cancer-Associated Venous Thromboembolic Disease Panel.